Delaware
|
94-3023969
|
(State or Other Jurisdiction of Incorporation)
|
(I.R.S. Employer Identification No.)
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Exhibit No.
|
Description
|
|
99.1
|
Presentation
|
PDL BIOPHARMA, INC.
|
||
(Company)
|
||
By:
|
/s/ Christine R. Larson
|
|
Christine R. Larson
|
||
Vice President and Chief Financial Officer
|
Exhibit No.
|
Description
|
|
Presentation
|
Company
|
PDL BioPharma, Inc.
|
Ticker
|
PDLI (NASDAQ)
|
Location
|
Incline Village, Nevada
|
Employees
|
Less than 10
|
2010 Revenues
|
$345 million
|
2011- Q3YTD Revenue
Guidance |
$288 million
|
2011 Regular Dividends
|
$0.15 /share paid on March 15, June 15,
September 15 & December 15 |
Q2-2011 Cash Position1
|
$236 million
|
Shares O/S2
|
~ 140 million
|
Average Daily Volume
|
~ 3 million shares
|
Genentech Product Made or Sold in U.S.
|
|
Net Sales up to $1.5 Billion
|
3.0%
|
Net Sales Between $1.5 Billion and $2.5 Billion
|
2.5%
|
Net Sales Between $2.5 Billion and $4.0 Billion
|
2.0%
|
Net Sales Over $4.0 Billion
|
1.0%
|
Genentech Product Made and Sold Ex-U.S.
|
|
All Sales
|
3.0%
|
9@2>:KRV8#$F1B3ZBG9V"Z%COE8`2K@^HJVI#KE&R*S3
M"J]R:%)B.4.*$WU"Q=DC)J!H]IR<"KNS*:T0/85#'*4.#R
M*M`Y&:M68MB'85^ZQ%`:0=@U34A4&BP$8F'<$4\.K="*"F>],,0]/RHU`EHJ
M#:R_=U',^X713-EI@7)T;3/_``%3_"H7M]-4
M<:-I?_@(M79!@&J